Adverse Event reporting information can be found in footer

Request a Meeting

PI
Firmagon degarelix. Think beyond the prostate Icon Icon Icon Icon

The economic burden of CVD in the UK

DEGARELIX FERRING reduces the risk of CV events vs. LHRH agonists1-5,15
Learn More...
How much are CVD-related healthcare costs estimated to be annually in each UK country?6,7
Hover over the map to find out
£800 million annually in Scotland, Data for England suggests that one event costs an estimated average of £3,449.2,3
£412 million annually for Northern Ireland. Data for England suggests that one event costs an estimated average of £3,449.2,3
£550 million annually in Wales,
Data for England suggests that one event costs an estimated average of £3,449.2,3
£7.4 billion annually in England3,
with one event costing an estimated average of £3,4492,3

If you would like to access your local ICS level data…

Tools to help manage cardiovascular risk in your patients

To minimise the number of CV events, risk assessment and risk-reduction measures are important prior to starting ADT.9-10

Below you can find both the STAMP tool and the CV risk assessment tool to help you assess your prostate cancer patients.

STAMP - Identification of patients with CVD11

S
Stroke
T
Transient ischaemic attack
A
Abdominal aortic aneurysm or other aortic disease
M
Myocardial infarction, angina, or previous coronary revascularisation
P
Peripheral arterial disease
Guideline-recommended interventions for men with PCa at high CV risk
EAU GUIDELINES12

“There is a suggestion in some studies and a SR and meta-analysis that cardiovascular side effects are less frequent in patients treated with LHRH antagonists than patients treated with LHRH agonists therefore patients with pre-existing cardiovascular disease or other cardiovascular risk factors might be considered to be treated with antagonists if a chemical castration is chosen”.

CUA GUIDELINES13

Use of a GnRH antagonist may be considered in men with a prior history of myocardial infarction or stroke, or with significant cardiac comorbidities

“It might be time to consider treating men who have pre-existing CV risk factors with a GnRH antagonist rather than an agonist.’’ 14

The CV risk assessment tool10

CV risk assessment tool

Adapted from Davey P and Alexandrou P. 202210

▲ SECTION NAVIGATION ▲